Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
Type:
Grant
Filed:
July 20, 2010
Date of Patent:
July 3, 2012
Assignee:
KMT Hepatech, Inc.
Inventors:
Norman M. Kneteman, D. Lorne Tyrrell, David Frederick Mercer
Abstract: An article suitable for conducting one or more assays with an apparatus, e.g., a meter, for determining the presence or concentration of an analyte in a sample of biological fluid. The article contains a plurality of biosensors arranged in such a manner that each of the biosensors can be utilized before the article must be removed from the apparatus.
Type:
Grant
Filed:
September 17, 2004
Date of Patent:
July 3, 2012
Assignee:
Abbott Diabetes Care Inc.
Inventors:
Yi Wang, Jared Lee Watkin, Chad Harold Mace, Michael Robert Zocchi, Shridhara Alva Karinka, Mark E. Tess
Abstract: The present invention provides a method of producing a planar lipid bilayer on a solid support. With this method, a solution of lipid vesicles is first deposited on the solid support. Next, the lipid vesicles are destabilized by adding an amphipathic peptide solution to the lipid vesicle solution. This destabilization leads to production of a planar lipid bilayer on the solid support. The present invention also provides a supported planar lipid bilayer, where the planar lipid bilayer is made of naturally occurring lipids and the solid support is made of unmodified gold or titanium oxide. Preferably, the supported planar lipid bilayer is continuous. The planar lipid bilayer may be made of any naturally occurring lipid or mixture of lipids, including, but not limited to phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinsitol, cardiolipin, cholesterol, and sphingomyelin.
Type:
Grant
Filed:
March 29, 2006
Date of Patent:
July 3, 2012
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Nam-Joon Cho, Curtis W. Frank, Jeffrey S. Glenn, Kwang Ho Cheong
Abstract: The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations.
Type:
Grant
Filed:
May 2, 2011
Date of Patent:
June 26, 2012
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Omar D. Perez, Garry P. Nolan, Jonathan M. Irish
Abstract: A method of determining the percentage of glycated hemoglobin in a blood sample is disclosed wherein at least one of the assay steps is performed electrochemically. The method includes determining the total amount of hemoglobin in a sample by electrochemically measuring, in an oxygen electroreduction reaction at a cathode, the amount of oxygen in the sample. Because the amount of oxygen dissolved in the sample is known, the total hemoglobin is determined by subtracting the amount of free oxygen from the total oxygen measured, recognizing the fast equilibrium Hb+O2?HbO2. This can be followed by determining the amount of glycated hemoglobin in the sample. The cathode reaction is accomplished by contacting the sample with an enzyme, the enzyme being a copper-containing enzyme having four copper ions per active unit. The family of these enzymes includes, for example, laccases and bilirubin oxidases. A device associated with such a process or method is also provided.
Abstract: The present invention relates to hemostatic compositions comprising a mesocellular oxide foam and, optionally, a biologically active agent such as a procoagulant, as well as devices and methods of use to promote blood clotting.
Type:
Grant
Filed:
August 13, 2008
Date of Patent:
June 19, 2012
Assignee:
The Regents of the University of California
Inventors:
Galen Stucky, Sarah Baker, April Sawvel
Abstract: Methods for evaluating tissue motion of a tissue location, e.g., a cardiac location, via external continuous field tomography are provided. Aspects of the methods include generating at least one substantially linear continuous field gradient across the tissue location of interest, and using a resultant signal from a sensing element stably associated with the tissue location to evaluate motion of the tissue location. Also provided are systems, devices and related compositions for practicing the subject methods. The subject methods and devices find use in a variety of different applications, including cardiac resynchronization therapy.
Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.
Type:
Grant
Filed:
April 26, 2011
Date of Patent:
June 12, 2012
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Type:
Grant
Filed:
January 19, 2011
Date of Patent:
June 12, 2012
Assignees:
Genomic Health, Inc., NSABP Foundation, Inc.
Inventors:
Drew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
Abstract: Site-specific Listeria integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source of these elements is a listeriophage. In certain embodiments, the subject vectors further include a multiple cloning site, where the multiple cloning site may further include a polypeptide coding sequence, e.g., for a heterologous antigen. The subject vectors and methods find use in a variety of different applications, including the study of Listeria species and the preparation of Listeria vaccines.
Type:
Grant
Filed:
May 19, 2010
Date of Patent:
June 5, 2012
Assignee:
The Regents of the University of California
Inventors:
Daniel A. Portnoy, Richard Lane Calendar, Peter M. Lauer
Abstract: Implantable hermetically sealed structures and methods for making the same. Devices, systems and kits including the hermetically sealed structures, as well as methods of using such devices and systems are included.
Type:
Grant
Filed:
December 22, 2005
Date of Patent:
June 5, 2012
Assignee:
Proteus Biomedical, Inc.
Inventors:
Jeremy Frank, Vladimier Gelfandbein, Marc Jensen, Mark J. Zdeblick, Benedict James Costello
Abstract: The present invention features polypeptides having activity of human neurogenin3 (hNgn3), and nucleic acid encoding such polypeptide. The invention also features use of islet transcription factors such as hNgn3 to facilitate production of pancreatic islet cells from progenitor cells, and to facilitate insulin delivery by production of islet cells so produced.
Type:
Grant
Filed:
August 14, 2003
Date of Patent:
June 5, 2012
Assignee:
The Regents of the University of California
Abstract: A sensor utilizing a non-leachable or diffusible redox mediator is described. The sensor includes a sample chamber to hold a sample in electrolytic contact with a working electrode, and in at least some instances, the sensor also contains a non-leachable or a diffusible second electron transfer agent. The sensor and/or the methods used produce a sensor signal in response to the analyte that can be distinguished from a background signal caused by the mediator. The invention can be used to determine the concentration of a biomolecule, such as glucose or lactate, in a biological fluid, such as blood or serum, using techniques such as coulometry, amperometry, and potentiometry. An enzyme capable of catalyzing the electrooxidation or electroreduction of the biomolecule is typically provided as a second electron transfer agent.
Type:
Grant
Filed:
September 29, 2009
Date of Patent:
June 5, 2012
Assignee:
Abbott Diabetes Care Inc.
Inventors:
Benjamin J. Feldman, Adam Heller, Ephraim Heller, Fei Mao, Joseph A. Vivolo, Jeffery V. Funderburk, Fredric C. Colman, Rajesh Krishnan
Abstract: Various aspects of the present invention enable robust, reliable control functionality for effectors present on intraluminal, e.g., vascular leads, as well as other types of implantable devices. Aspects of the invention include implantable integrated circuits that have self-referencing and self-clocking signal encoding, and are capable of bidirectional communication. Also provided by the invention are effector assemblies that include the integrated circuits, as well as implantable medical devices, e.g., pulse generators that include the same, as well as systems and kits thereof and methods of using the same, e.g., in pacing applications, including cardiac resynchronization therapy (CRT) applications.
Type:
Grant
Filed:
August 29, 2008
Date of Patent:
May 29, 2012
Assignee:
Proteus Biomedical, Inc.
Inventors:
Haifeng Li, Mark Zdeblick, Lawrence Arne, Yafei Bi, Nilay Jani, Jonathan Withrington
Abstract: A sensor utilizing a non-leachable or diffusible redox mediator is described. The sensor includes a sample chamber to hold a sample in electrolytic contact with a working electrode, and in at least some instances, the sensor also contains a non-leachable or a diffusible second electron transfer agent. The sensor and/or the methods used produce a sensor signal in response to the analyte that can be distinguished from a background signal caused by the mediator. The invention can be used to determine the concentration of a biomolecule, such as glucose or lactate, in a biological fluid, such as blood or serum, using techniques such as coulometry, amperometry, and potentiometry. An enzyme capable of catalyzing the electrooxidation or electroreduction of the biomolecule is typically provided as a second electron transfer agent.
Type:
Grant
Filed:
April 13, 2007
Date of Patent:
May 29, 2012
Assignee:
Abbott Diabetes Care Inc.
Inventors:
Benjamin J. Feldman, Adam Heller, Ephraim Heller, Fei Mao, Joseph A. Vivolo, Jeffery V. Funderburk, Fredric C. Colman, Rajesh Krishnan
Abstract: A sensor utilizing a non-leachable or diffusible redox mediator is described. The sensor includes a sample chamber to hold a sample in electrolytic contact with a working electrode, and in at least some instances, the sensor also contains a non-leachable or a diffusible second electron transfer agent. The sensor and/or the methods used produce a sensor signal in response to the analyte that can be distinguished from a background signal caused by the mediator. The invention can be used to determine the concentration of a biomolecule, such as glucose or lactate, in a biological fluid, such as blood or serum, using techniques such as coulometry, amperometry, and potentiometry. An enzyme capable of catalyzing the electrooxidation or electroreduction of the biomolecule is typically provided as a second electron transfer agent.
Type:
Grant
Filed:
September 29, 2009
Date of Patent:
May 29, 2012
Assignee:
Abbott Diabetes Care Inc.
Inventors:
Benjamin J. Feldman, Adam Heller, Ephraim Heller, Fei Mao, Joseph A. Vivolo, Jeffery V. Funderburk, Fredric C. Colman, Rajesh Krishnan
Abstract: The present invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease.
Type:
Grant
Filed:
November 22, 2005
Date of Patent:
May 29, 2012
Assignee:
The Board of Trustees of the Leland Stanford Jr. University
Inventors:
John Cooke, James Jang, Phillip Tsao, Christopher Heeschen
Abstract: Co-topo-polymeric indicator compositions and methods for making and using the same are provided. Indicator compositions of the invention include a polymer and undergo a color change, which may be reversible or irreversible, in response to an applied stimulus, e.g., temperature. Aspects of methods of producing the compositions include setting a fluid co-topo-polymeric precursor composition into a solid product and then subjecting the solid product (either immediately or after a delay period) to polymerizing conditions to produce the desired indicator composition. Also provided are indicator devices that include the indicator compositions of the invention. The compositions of the invention find use in a variety of different applications.
Abstract: A sensor utilizing a non-leachable or diffusible redox mediator is described. The sensor includes a sample chamber to hold a sample in electrolytic contact with a working electrode, and in at least some instances, the sensor also contains a non-leachable or a diffusible second electron transfer agent. The sensor and/or the methods used produce a sensor signal in response to the analyte that can be distinguished from a background signal caused by the mediator. The invention can be used to determine the concentration of a biomolecule, such as glucose or lactate, in a biological fluid, such as blood or serum, using techniques such as coulometry, amperometry; and potentiometry. An enzyme capable of catalyzing the electrooxidation or electroreduction of the biomolecule is typically provided as a second electron transfer agent.
Type:
Grant
Filed:
September 29, 2009
Date of Patent:
May 22, 2012
Assignee:
Abbott Diabetes Care Inc.
Inventors:
Benjamin J. Feldman, Adam Heller, Ephraim Heller, Fei Mao, Joseph A. Vivolo, Jeffery V. Funderburk, Fredric C. Colman, Rajesh Krishnan